Abstract:The mechanistic target of rapamycin (mTOR) pathway integrates metabolic cues into cell fate decisions. A particularly fateful event during the adaptive immune response is the engagement of a T cell receptor by its cognate antigen presented by an antigen-presenting cell (APC). Here, the induction of adequate T cell activation and lineage specification is critical to mount protective immunity; at the same time, inadequate activation, which could lead to autoimmunity, must be avoided. mTOR forms highly conserved protein complexes 1 and 2 that shape lineage specification by integrating signals originating from TCR engagement, co-stimulatory or co-inhibitory receptors and cytokines and availability of nutrients. If one considers autoimmunity as the result of aberrant lineage specification in response to such signals, the importance of this pathway becomes evident; this provides the conceptual basis for mTOR inhibition in the treatment of systemic autoimmunity, such as systemic lupus erythematosus (SLE). Clinical trials in SLE patients have provided preliminary evidence that mTOR blockade by sirolimus (rapamycin) can reverse pro-inflammatory lineage skewing, including the expansion of Th17 and double-negative T cells and plasma cells and the contraction of regulatory T cells. Moreover, sirolimus has shown promising efficacy in the treatment of refractory idiopathic multicentric Castleman disease, newly characterized by systemic autoimmunity due to mTOR overactivation. Alternatively, mTOR blockade enhances responsiveness to vaccination and reduces infections by influenza virus in healthy elderly subjects. Such seemingly contradictory findings highlight the importance to further evaluate the clinical effects of mTOR manipulation, including its potential role in treatment of COVID-19 infection. mTOR blockade may extend healthy lifespan by abrogating inflammation induced by viral infections and autoimmunity. This review provides a mechanistic assessment of mTOR pathway activation in lineage specification within the adaptive and innate immune systems and its role in health and autoimmunity. We then discuss some of the recent experimental and clinical discoveries implicating mTOR in viral pathogensis and aging.

Mtor Signaling in T Cell Immunity and Autoimmunity

Modulation of TSC-mTOR Signaling on Immune Cells in Immunity and Autoimmunity.

Mtorc1, the Master Regulator of Autophagy

The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism

mTORC1 and mTORC2 as regulators of cell metabolism in immunity

Nutrient Mtorc1 Signaling Underpins Regulatory T Cell Control of Immune Tolerance

Mtor Signaling: A Pivotal Player in Treg Cell Dysfunction in Systemic Lupus Erythematosus.

Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan

The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses

Regulation of Hematopoietic Stem Cells Differentiation, Self-Renewal, and Quiescence Through the Mtor Signaling Pathway

mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment

Roles of Mtor Signaling in Tissue Regeneration

Mtor Signaling in Stem and Progenitor Cells

mTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications?

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

mTORC2: a multifaceted regulator of autophagy

Mtor Signaling in Cardiometabolic Disease, Cancer, and Aging

Mtor Signaling Disruption From Myeloid-Derived Suppressive Cells Protects Against Immune-Mediated Hepatic Injury Through The Hif1 Alpha-Dependent Glycolytic Pathway

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process